Catalog No.S1373 Synonyms: LY146032
Molecular Weight(MW): 1620.67
Daptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.
Cited by 11 Publications
3 Customer Reviews
Same experiment as in Figure 2 with fluorescent daptomycin shown as confocal images. A 7/3 DOPC/DOPG GUV (including 1% Rh-PE) was introduced at time zero into a solution containing 1 uM daptomycin with 0.5 uM BODIPY-daptomycin and 1 mM Ca2+. To show colocalization of lipid and peptide in aggregates, confocal images were taken: red for RH-PE and green for BODIPY-daptomycin. As the protrusion length decreased, aggregates appeared on the GUV surface containing both lipid and peptide. The scale bar is 10 um.
Biochemistry 2014 53(33), 5384-92. Daptomycin purchased from Selleck.
Stoichiometry of daptomycin and calcium binding to PG-containing membranes. The experimental data are the fraction of 40 μM daptomycin in the B state, ϕ, as a function of Ca2+ concentration at different lipid concentrations. The lipids were DOPC/DOPG 7:3 in SUVs. The error bars represent the range of reproducibility for three independent measurements.
Biophys J, 2017, 113(1):82-90. Daptomycin purchased from Selleck.
Membrane permeability induced by CCCP and daptomycin in E. coli spheroplasts. Experiments were conducted as described in Fig. 1a, but with different chemicals or fluorescent dyes. (a) Calcein and sytox orange (SO) permeability induced by CCCP (100 µM) in E. coli membranes is shown. The SO signal is represented as an increase from the initial state, (F-F0)/F0. (b) Calcein permeability induced by 1 µM daptomycin with 1 mM CaCl2.
Biophys J, 2017, 112(8):1663-1672. Daptomycin purchased from Selleck.
Purity & Quality Control
Choose Selective DNA/RNA Synthesis Inhibitors
|Description||Daptomycin is a novel antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.|
Daptomycin (5 μg/ml) reduces cell viability by >99% and membrane potential by >90% within 30 min in Staphylococcus aureus. Daptomycin exhibits rapid in vitro bactericidal activity against clinically significant strains of gram-positive pathogens including hemolytic streptococci, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant enterococci. Daptomycin acts at the cytoplasmic membrane of susceptible bacteria (8), as demonstrated by binding and fractionation studies. Daptomycin also differs from that of some antimicrobial peptides (e.g., human neutrophil peptide 1) that are capable of rapid depolarization of the cytoplasmic membrane but do not induce cell death for 1 hour to 2 hours. Daptomycin inserts into the cytoplasmic membrane of bacteria, as indicated by whole-cell and artificial membrane studies.  Daptomycin demonstrates greater bactericidal activity than all other drugs tested, killing ≥3 log CFU/ml by 8 hours. Daptomycin is a cyclic polypeptide derived from Streptomyces roseosporus and representing a class of antimicrobial agents known as the peptolides (acid lipopeptide antibiotics). Daptomycin is also active against vancomycin-resistant gram-positive bacteria, including enterococci. Daptomycin is highly protein bound (94%), and its in vitro activity is altered in the presence of serum or albumin. Daptomycin consists of a 13-member amino acid cyclic lipopeptide with a decanoyl side-chain, the lipophilic Daptomycin tail into the bacterial cell membrane, causing rapid membrane depolarization and a potassium ion efflux. Daptomycin treatment has been linked to fully reversible skeletal muscle toxicity with no effect on smooth or cardiac muscle. 
|In vivo||Daptomycin exhibited linear pharmacokinetics, with an area under the concentration-time curve (AUC) from time zero to infinity/dose of 9.4 and a half-life of 0.9 to 1.4 h. The level of protein binding was 90%.|
-  Silverman JA, et al. Antimicrob Agents Chemother, 2003, 47(8), 2538-2544.
-  Rybak MJ, et al. Antimicrob Agents Chemother, 2000, 44(4), 1062-1066.
-  Steenbergen JN, et al. J Antimicrob Chemother, 2005, 55(3), 283-288.
|In vitro||DMSO||100 mg/mL (61.7 mM)|
|Water||100 mg/mL warmed (61.7 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03134521||Unknown status||--||Bone Infection|Joint Infection||Hospices Civils de Lyon||December 1 2016||--|
|NCT03004066||Completed||Drug: Daptomycin||Heart Assist Device||University Hospital Tuebingen||October 2016||--|
|NCT03209921||Completed||--||Bone and Joint Infection|Patient Treated by Daptomycin||Hospices Civils de Lyon||May 2015||--|
|NCT02241941||Withdrawn||Drug: Daptomycin||Burn Injury||University of Zurich||September 2014||Phase 4|
|NCT03209934||Completed||--||Bone and Joint Infection|Treated by Daptomycin||Hospices Civils de Lyon||July 2014||--|
|NCT02097953||Completed||Drug: Daptomycin|Drug: Rifampin||Drug Interactions|Pharmacokinetics||University of Utah|Cubist Pharmaceuticals LLC||May 2014||Early Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Frequently Asked Questions
Could you tell me the native source for this product?
Daptomycin was synthesed from S.reseosporus.